Ascendis Pharma A/S reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was EUR 1.11 million compared to EUR 2.76 million a year ago. Net loss was EUR 80.35 million compared to EUR 121.74 million a year ago. Basic loss per share from continuing operations was EUR 1.47 compared to EUR 2.31 a year ago. For the nine months, sales was EUR 2.88 million compared to EUR 6.42 million a year ago. Net loss was EUR 277.52 million compared to EUR 279.99 million a year ago. Basic loss per share from continuing operations was EUR 5.13 compared to EUR 5.64 a year ago.